KPWS
RNA

Kestra Private Wealth Services’s Atrium Therapeutics RNA Stock Holding History

Kestra Private Wealth Services’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139K Buy
+10,370
New +$135K ﹤0.01% 1722

Other funds holding RNA

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FI
Fractal Investments Glastonbury, Connecticut $867M AUM 23.63% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Kestra Private Wealth Services's RNA Position: Q2 2026 in Review

Kestra Private Wealth Services opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 10,370 shares worth $139K. The stake represents ﹤0.01% of the portfolio and ranks #1722 among its holdings.

24 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Kestra Private Wealth Services held 10,370 shares of Atrium Therapeutics worth $139K as of Q2 2026.
  • Atrium Therapeutics was a new Kestra Private Wealth Services position in Q2 2026.
  • Atrium Therapeutics made up ﹤0.01% of Kestra Private Wealth Services's portfolio in Q2 2026, its #1722 holding.
  • 24 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Kestra Private Wealth Services's 13F filing for Q2 2026, filed 28 Jul 2026.